Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Change in Accured Expenses (2019 - 2025)

Harmony Biosciences Holdings' Change in Accured Expenses history spans 7 years, with the latest figure at $52.5 million for Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 317.11% year-over-year to $52.5 million; the TTM value through Dec 2025 reached $68.0 million, up 476.27%, while the annual FY2025 figure was $68.0 million, 476.27% up from the prior year.
  • Change in Accured Expenses for Q4 2025 was $52.5 million at Harmony Biosciences Holdings, up from $28.0 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $52.5 million in Q4 2025 and bottomed at -$22.8 million in Q4 2022.
  • The 5-year median for Change in Accured Expenses is $5.9 million (2021), against an average of $8.2 million.
  • The largest annual shift saw Change in Accured Expenses skyrocketed 535.86% in 2022 before it tumbled 637.48% in 2024.
  • A 5-year view of Change in Accured Expenses shows it stood at $8.7 million in 2021, then crashed by 360.98% to -$22.8 million in 2022, then surged by 235.23% to $30.8 million in 2023, then plummeted by 59.13% to $12.6 million in 2024, then skyrocketed by 317.11% to $52.5 million in 2025.
  • Per Business Quant, the three most recent readings for HRMY's Change in Accured Expenses are $52.5 million (Q4 2025), $28.0 million (Q3 2025), and -$7.0 million (Q2 2025).